Calidi Biotherapeutics Inc (CLDI) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks significant positive trading signals, has weak financial performance, and no clear upward trend in technical indicators. While the company has promising developments in its RedTail platform, these are early-stage and speculative. Given the lack of immediate catalysts and the company's financial struggles, it is better to hold off on investing in this stock for now.

Technical Analysis

The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 62.866, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 0.866), suggesting limited upside potential in the short term.

Positive Catalysts

The company presented promising data on its RedTail platform at the AACR Immuno-Oncology conference, showcasing potential advancements in T-cell activation for solid tumors. Additionally, it is conducting IND-enabling studies for CLD-401 and plans to submit an IND application by the end of 2026.

Neutral/Negative Catalysts

EPS dropped significantly by -71.48% YoY. There is no significant trading activity from hedge funds, insiders, or Congress, and no valuation data is available.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of -$10.82 million, which improved by 114.13% YoY. However, EPS dropped significantly to -2.21 (-71.48% YoY), reflecting poor profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast CLDI stock price to rise

Buy

Hold

Sell

Current: 0.782

Low

Averages

High